Dr. Stephen R. Walsh, MDCM
Infectious Disease (Infectious Disease Physician)
- Medicare participating
At a glance
- Years since graduation
- 28
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 54
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Infectious Disease Physician primary
MA license 205960 -
Internal Medicine Physician
MA license 205960
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Brigham and Women's Hospital Boston, MA
Medical groups
- Brigham and Womens Physicians Organization Inc (2,994 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 54
- Services billed
- 143
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 85 | 49 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 62 | 41 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 52 | 51 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $34,800 in total to this clinician.
| Csl Behring | $34,800 |
|---|
| Consulting Fee | $34,800 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Csl Behring Jun 11, 2025 | Consulting Fee Hizentra · Immunology | $34,800 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $31,911 in research payments for these studies, mostly to the institutions running them.
- A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19
ModernaTX, Inc. · Completed · NCT05815498 - A Phase 3 Randomized Open label Study to Assess the Immunogenicity and Safety of IVX A12 when Co-administered with a licensed influenza vaccine
AstraZeneca Pharmaceuticals LP - BNT166-02
BioNTech SE
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.